Explore

Insilico Medicine Utilizes AI to Discover Potential Anti-Aging Drug Rentosertib

Insilico Medicine Utilizes AI to Discover Potential Anti-Aging Drug Rentosertib

Insilico Medicine, an AI-driven drug discovery company, has announced that its drug candidate, rentosertib, initially developed for idiopathic pulmonary fibrosis (IPF), shows potential in slowing the aging process. The drug's molecular structure was assisted by artificial intelligence. New data from a clinical trial, published in Nature Biotechnology, indicates that rentosertib reduces biological markers of age as measured by six different 'aging clocks'—AI technology designed to predict morbidity and mortality. While the clinical trial involved only 42 patients with chronic lung disease, the findings suggest a broader application beyond its initial purpose. This development highlights the growing role of AI in accelerating drug discovery and potentially identifying novel anti-aging treatments, a field that has historically seen many failures in developing new drugs.

Mayo Clinic Research Suggests Hormone Therapy Enhances Tirzepatide Weight Loss in Postmenopausal Women

Mayo Clinic Research Suggests Hormone Therapy Enhances Tirzepatide Weight Loss in Postmenopausal Women

New research from the Mayo Clinic indicates that postmenopausal women combining hormone therapy with tirzepatide experienced significantly greater weight loss compared to those using tirzepatide alone. A study involving 120 postmenopausal women with overweight or obesity found that participants receiving both treatments lost an average of 19.2% of their initial body weight, a 35% greater reduction than the 14.0% observed in women using tirzepatide exclusively. Furthermore, 45% of women on combined therapy achieved at least a 20% body weight loss, whereas only 18% of those on tirzepatide alone reached this milestone. Both groups showed improvements in metabolic health, but women on hormone therapy also saw notable reductions in diastolic blood pressure, triglycerides, and the liver enzyme AST. This finding aligns with a previous Mayo Clinic study on semaglutide, suggesting a broader pattern across incretin-based therapies where hormone therapy may create a more favorable metabolic environment.

GLP-1 Medications Show Promise in Cardiovascular Health Beyond Weight Loss, Complementing Statins

GLP-1 Medications Show Promise in Cardiovascular Health Beyond Weight Loss, Complementing Statins

GLP-1 medications, such as Ozempic and Mounjaro, are demonstrating significant cardiovascular benefits that extend beyond their well-known effects on weight loss. Cardiologists are increasingly viewing GLP-1s as a complementary treatment to statins, rather than a replacement, in managing cardiovascular risk. While statins primarily lower LDL ('bad') cholesterol by blocking an enzyme in the liver, GLP-1s work by mimicking a naturally occurring hormone that regulates blood sugar, appetite, and feelings of fullness. According to Dr. Arash Bereliani, a cardiologist, GLP-1s improve metabolic factors like blood sugar, triglycerides, blood pressure, and inflammation, which can strain the cardiovascular system. Dr. Fadi Alameddine, another cardiologist, emphasizes that GLP-1s barely affect LDL but significantly impact weight, inflammation, blood sugar, blood pressure, and vascular health. Studies have shown that GLP-1-based therapies can reduce inflammation markers, improve blood vessel function by enhancing the e...

NIH Awards Multi-University Team Over $4M to Improve Women's Health Through Computational Modeling

NIH Awards Multi-University Team Over $4M to Improve Women's Health Through Computational Modeling

The National Institutes of Health (NIH) has awarded a multi-university team, led by Michigan State University, over $4 million as the first installment of a potential $12.8 million grant. This funding will support a novel project aimed at transforming how medications are developed and prescribed for women. The research team, comprising 13 researchers from institutions including Rutgers, Emory, and the University of Colorado Anschutz, will build advanced computer models. These models are designed to predict how women's natural hormonal changes throughout their lifespan—such as during menstrual cycles, pregnancy, birth control use, menopause, and hormone replacement therapy—affect how medicines interact with their bodies. The goal is to address the current gap where clinical trials often fail to account for these unique hormonal fluctuations, leading to less effective treatments or more severe side effects in women.

New Study Links GLP-1 Weight Loss Drugs to Rare Brain Condition

New Study Links GLP-1 Weight Loss Drugs to Rare Brain Condition

A recent Israeli study has identified a potential link between GLP-1 weight loss and diabetes drugs and a rare, serious brain condition called Wernicke encephalopathy. The study, which reviewed U.S. Food and Drug Administration’s adverse event reports and related literature, found 15 cases of Wernicke encephalopathy between 2023 and 2024 in individuals taking these medications. Wernicke encephalopathy is a life-threatening neurological disorder caused by a severe deficiency of vitamin B1, which can lead to permanent memory loss and an inability to form new memories. Experts emphasize that this condition is rare, with only 15 cases identified out of millions of people using GLP-1 drugs. Most of the reported cases involved patients experiencing gastrointestinal side effects such as vomiting, diarrhea, and loss of appetite, which can lead to malnutrition and vitamin B1 deficiency. The majority of these cases were associated with semaglutide-based drugs like Ozempic and Wegovy, or tirzepatide GLP-1s such as Ze...

Feinstein Institutes Awarded $8.9M Grant for Advanced Care Planning in Older Adults and Dementia Patients

Feinstein Institutes Awarded $8.9M Grant for Advanced Care Planning in Older Adults and Dementia Patients

Northwell Health’s Feinstein Institutes for Medical Research has received an $8.9 million multi-year grant from the National Institutes of Health’s (NIH) National Institute on Aging (NIA). This funding is part of a larger NIA grant exceeding $40 million. The grant will support the Advancing Ethical Goals in Society (AEGIS) clinical trial, a collaborative effort with Tufts University and Dartmouth Health. The AEGIS trial aims to transform advanced care planning for older adults and individuals with Alzheimer’s disease and related dementias (AD/ADRD). Dr. Edith Burns, a professor at the Institute of Health System Science at the Feinstein Institutes, will lead the trial. Co-investigators include Dr. Santiago Lopez, interim chief of Geriatrics and Palliative Medicine for Northwell Health’s central market, and Dr. Philip Solomon, director of Faculty Development and Education, Northwell Institute for Healthy Aging. The program will develop video education tools and deploy trained Advanced Care Planning (ACP) edu...

Researchers Investigate Biological and Lifestyle Factors Influencing Healthy Aging

Researchers Investigate Biological and Lifestyle Factors Influencing Healthy Aging

Researchers are actively studying various biological and lifestyle factors that influence healthy aging, moving beyond the traditional view of aging as solely a process of decline. Key areas of focus include muscle health, nutrition, sleep, cognitive function, cellular processes, and social connection. Scientists are examining how muscle tissue changes with age and how physical activity, resistance exercise, recovery, and nutrition can support muscle function. Nutrition research considers how appetite, digestion, activity levels, and daily routines change, with particular attention to protein intake for muscle maintenance. At the cellular level, studies are investigating why cells function differently with age, focusing on energy production, molecular signaling, and repair mechanisms. Brain health research extends beyond memory to include attention, reasoning, language, emotional well-being, and the ability to manage daily tasks. Sleep patterns and their relationship with physical and cognitive health are ...

Arbor's GLP-1 plans start at $99 per month. Get started in 90 seconds

Arbor's GLP-1 plans start at $99 per month. Get started in 90 seconds

Arbor connects eligible patients with licensed providers who can prescribe compounded GLP-1 weight loss medications online. Plans start at $99 per month.

Zenbody RX Launches Telehealth Platform for Personalized Weight Management and Future Longevity Treatments

Zenbody RX Launches Telehealth Platform for Personalized Weight Management and Future Longevity Treatments

Zenbody RX has introduced a new telehealth platform designed to offer personalized, clinician-guided weight management services. The platform integrates online assessment, provider review, individualized treatment, home delivery of medication, and ongoing support into a single care pathway. Initially, Zenbody RX is focusing on GLP-1 medications, specifically compounded semaglutide and tirzepatide, for eligible weight-management patients. The company emphasizes a connected model where technology simplifies access while maintaining clinical decision-making and personalized care at the forefront. Patients can track progress, receive coaching, communicate with their care team, and complete regular check-ins through the Zenbody app. Austin Rampt, a representative of Zenbody RX, stated that the goal is to make care simpler without making it impersonal, ensuring patients understand their treatment and have continuous clinical support. The process begins with a brief online intake, followed by a licensed provider'...

The supplement behind the C15:0 trend is now available as a gummy

The supplement behind the C15:0 trend is now available as a gummy

The popular Fatty15 supplement is now available in gummy form. Discover the benefits of C15:0, ingredients, flavor and current pricing.

Scientists Identify Protein Allowing Aging Cells to Evade Immune System, Opening Avenues for Healthspan Treatments

Scientists Identify Protein Allowing Aging Cells to Evade Immune System, Opening Avenues for Healthspan Treatments

Researchers have identified a protein, PD-L2, that allows senescent cells—worn-out cells that accumulate with age and release inflammatory signals—to evade the body's immune system. This discovery, reported in a new peer-reviewed study by Cedars-Sinai, indicates that senescent human cells produce more PD-L2 than younger cells, with levels increasing in some human tissues with age. In mouse studies, genetically removing or experimentally blocking PD-L2 led to a reduction in senescent-cell accumulation and lowered inflammatory signals. These mice also showed improved health measures, including glucose processing and grip strength. This suggests that PD-L2 acts as a 'disguise,' making it harder for the immune system to eliminate these persistent, potentially harmful cells. The research is significant not as a direct anti-aging treatment for humans, but as an identification of a mechanism contributing to the persistence of unwanted senescent cells.

Sesame Care Offers Marketplace Model for GLP-1 Treatments with Variable Pricing

Sesame Care Offers Marketplace Model for GLP-1 Treatments with Variable Pricing

Sesame Care operates as a marketplace that connects patients with independent clinicians for various healthcare needs, including GLP-1 treatments. Unlike many other programs that publish standardized medication pricing, Sesame Care's model means that visit and program fees, as well as medication costs, vary by the individual provider selected and the patient's location. Consequently, patients do not find a stable, all-inclusive medication price publicly listed. Instead, they must request an individualized quote after going through an intake process and selecting a provider. This approach contrasts with seven verified alternative programs that offer transparent, month-to-month rates, such as PlexusDx, which provides compounded semaglutide injection for $189 monthly and compounded tirzepatide injection for $289 monthly, without a membership fee. Other alternatives like Eden offer slightly higher all-in costs but still maintain published rates.